Entasis Therapeutics (ETTX) Stock Analysis

What Entasis Therapeutics does

Entasis Therapeutics Holdings Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to the discovery, development, and market introduction of novel antibacterial solutions. Their core mission in the United States is to address severe infections stemming from pathogens that exhibit multidrug resistance. A flagship program in their pipeline is sulbactam-durlobactam (SUL-DUR), an innovative intravenous antibiotic. This promising candidate is currently undergoing Phase III clinical evaluation for its effectiveness in treating pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company's developmental efforts extend to several other therapeutic agents. Zoliflodacin, a distinct orally administered molecule, is also progressing through Phase III clinical trials, aimed at uncomplicated gonorrhea. Furthermore, ETX0282CPDP, an oral drug, is being assessed in Phase I studies for its potential in treating urinary tract infections. From their NBP platform, ETX0462 is another drug candidate, presently in the pre-clinical stage, targeting a range of multidrug-resistant gram-negative infections. Entasis maintains key partnerships to advance its portfolio. A licensing and collaboration agreement is in place with Zai Lab (Shanghai) Co., Ltd. for the continued development of durlobactam and SUL-DUR. Additionally, they have a collaborative arrangement with the Global Antibiotic Research and Development Partnership for the development and subsequent commercialization of Zoliflodacin. Established in 2015, Entasis Therapeutics Holdings Inc. maintains its corporate headquarters in Waltham, Massachusetts, and functions as a subsidiary of Innoviva, Inc.

Key metrics

ETFs linked to ETTX

Broad-market and Healthcare sector ETFs an investor holding Entasis Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ETTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Entasis Therapeutics?

Entasis Therapeutics trades under the ticker ETTX on NASDAQ.

Which exchange is ETTX listed on?

ETTX is listed on NASDAQ.

What sector does Entasis Therapeutics operate in?

Entasis Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ETTX in a portfolio?

PortView shows ETTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.